News | Genetic Testing | July 26, 2016

Genetic Error That Increases Risk of Aortic Rupture Identified

Study sheds light on unexplained enlargement, weakening of aorta

July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and similar errors at high risk of aortic aneurysms and ruptures. The findings will help diagnose, monitor and treat patients with aortic disease not caused by well-known conditions, such as Marfan syndrome and other genetic mutations known to disrupt connective tissues.

The study, led by Washington University School of Medicine in St. Louis, in collaboration with Brigham and Women’s Hospital in Boston, appears July 18 in the Proceedings of the National Academy of Sciences.

Working with the Brigham Genomic Medicine Program, the researchers identified the mutation in a family with a history of aortic disease but no known genetic reason for the condition. The error is in a gene called lysyl oxidase (LOX), which Washington University researchers have shown is responsible for connecting networks of tissue fibers that make up blood vessels.

The aorta is the body’s largest artery that carries blood from the heart to the rest of the body. A lifetime of smoking and poor cardiovascular health can lead to aortic aneurysms in older adults. But bulging and tearing of the aorta in a young person is most often due to an inherited condition.

A number of genetic mutations, including those that cause Marfan syndrome and Loeys-Dietz syndrome, are known to interfere with the integrity of connective tissues. Such weakening puts patients at high risk of death from a ruptured aorta. Standard genetic tests often pinpoint the reason for inherited aortic disease, but such tests can’t explain all cases.

“When a patient comes to the clinic with an enlarged aorta, clinicians can evaluate a standard list of genes to look for a cause of the condition,” said senior author Nathan O. Stitziel, M.D., Ph.D., a Washington University cardiologist and assistant professor of medicine. “Lysyl oxidase should now be added to the standard test panel. This type of information can provide clarity for families with histories of unexplained aortic aneurysms.”

The findings also may allow affected individuals to be identified early, before the aorta begins to enlarge, so that doctors can help these patients take steps to lower pressure on the aorta, and decide when surgery may be required to prevent a sudden rupture.

To confirm that this mutation was the cause of the weakened aorta rather than an association, Stitziel and his colleagues recreated the genetic mistake in mice using the gene editing technology CRISPR. Washington University’s Robert P. Mecham, Ph.D., the Alumni Endowed Professor of Cell Biology and Physiology, and graduate student Vivian Lee showed that mice with two copies of the mutated gene died of aortic rupture at birth. Mice with only one copy — like members of the family the researchers identified with the mutation — had disrupted collagen and elastin fibers in the aorta.

“The layers and fibers of the aorta are almost like the belts inside a tire,” Stitziel said. “You have to have the right structure to maintain the strength and integrity of the artery. Lysyl oxidase crosslinks the fibers together. When there is less lysyl oxidase than there should be, the proper structure is disrupted. And when lysyl oxidase is absent altogether, the mice don’t survive after birth.”

Stitziel added that the mouse model of the condition will enable the researchers to test new potential therapies for this type of aortic disease. In particular, the investigators pointed out that lysyl oxidase is known to perform its job of crosslinking fibers better when bound to copper, raising the possibility that such patients may benefit from therapies involving dietary copper.

“When we found this causal gene and were able to reveal it to the family, it was an emotional moment,” said Natasha Frank, M.D., a clinical geneticist who treated several members of the family at Brigham and Women’s Hospital. “Using genetic sequencing, we were able to answer the kind of question that hasn’t been possible to address before and potentially change the lives of family members who can now be tested for mutations in this gene.”

For more information: www.pnas.org

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init